T1	Participants 352 476	patients with metastatic non-small cell lung cancer (NSCLC) with disease progression on or after platinum-based chemotherapy
T2	Participants 478 580	Patients with epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations
T3	Participants 1933 2053	patients with metastatic non-small cell lung cancer whose disease has progressed on or after platinum-based chemotherapy
T4	Participants 2114 2148	patients with squamous cell tumors
T5	Participants 2173 2189	elderly patients
T6	Participants 2230 2349	patients with tumors harboring epidermal growth factor receptor or anaplastic lymphoma kinase genomic tumor aberrations
